

ASX Announcement

1 April 2025

Appointment of Company Secretary

Sydney, Australia – 1 April 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) advises that Nathan Jong of Acclime Australia has been appointed today as Company Secretary of OncoSil, succeeding Christian Dal Cin who announced his resignation on 18 March 2025.

Nathan has extensive experience with listed life science companies in corporate secretarial and finance roles. Nathan is a Chartered Accountant, Chartered Secretary and Fellow of the Governance Institute of Australia.

Nathan will be responsible for communication with the ASX in relation to listing rule matters, pursuant to ASX Listing Rule 12.6.

- END -

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Nathan Jong Company Secretary E: nathan.jong@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>